Oxford Biomedica PLC ORD 50P
Oxford Biomedica PLC ORD 50P/ GB00BDFBVT43 /
OXB
31.05.2024 21:00:00
|
Zm.
+10,5000
|
Wolumen |
Bid31.05.2024 |
Ask31.05.2024 |
Kapitalizacja Rynkowa |
St. dywidendy |
Wskaźnik C/Z |
331,0000GBX
|
+3,28%
|
114 283 Obrót(GBP): 375 383,3900 |
285,0000Wolumen Bid: 5 000 |
345,0000Wolumen Ask: 10 000 |
265,32 mlnGBP |
- |
- |
Opis działalności
Oxford BioMedica is a pioneer of gene and cell therapy, with a leading industry position in lentiviral vector and cell therapy research, development and manufacture.
Zarząd & Rada nadzorcza
CEO |
John Dawson |
Zarząd |
Stuart Paynter, Helen Stephenson-Ellis, James Miskin, Jason Slingsby, Kyriacos Mitrophanous, Matthew Treagus, Natalie Walter, Nick Page |
Rada nadzorcza |
Dr. Roch Doliveux, Dr. Michael Hayden, Dr. Sam Rasty, Heather Preston, John Dawson, Prof. Dame Kay Davies, Robert Ghenchev, Stuart Henderson, Stuart Paynter |
Główni akcjonariusze
Freefloat |
|
50,20% |
Vulpes Investment Management |
|
11,90% |
Novo Holdings |
|
10,00% |
M&G Investments |
|
8,70% |
Liontrust Asset Management |
|
5,00% |
Nine Ten Capital |
|
3,80% |
Hargreaves Lansdown Asset Management |
|
3,70% |
Mr. S M H Shah |
|
3,50% |
Artisan Partners |
|
3,20% |